Vaccine Therapy in Treating Patients With Advanced Melanoma
NCT ID: NCT00705640
Last Updated: 2016-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
45 participants
INTERVENTIONAL
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To assess the circulating CD8 T-cell response to vaccination with a multipeptide vaccine in patients with advanced melanoma.
* To determine whether immunization with peptides and incomplete Freund's adjuvant induces lymph-node-like aggregates (LNLA) and tertiary lymphoid organs (TLOs) in the skin of these patients.
* To determine whether extended immunization (vaccinations 4-6) is associated with induction of negative immune-regulatory processes in the vaccination site microenvironment/TLO.
* To characterize peptide-reactive CD4 and CD8 T cells in loco at sites of immunization with a multipeptide vaccine.
* To characterize the expression of toll-like receptors 4, 7, 8, and 9, and MyD88 in dendritic cells infiltrating vaccination sites over the course of 6 vaccinations and after vaccination.
OUTLINE: Patients are randomized to 1 of 10 arms.
All patients receive primary vaccine comprising melanoma multipeptides and tetanus toxoid helper peptide emulsified in incomplete Freund's adjuvant, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Vaccines are administered in a single skin location on an extremity clinically uninvolved with melanoma. A replicate vaccine site is identified for each patient for skin biopsy with or with out replica vaccine administration.
* Arm 1A: Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
* Arm 1B: Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
* Arm 1C: Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
* Arm 1D: Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
* Arm 1E: Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (6 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
* Arm 2A: Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
* Arm 2B: Patients receive replicate vaccine (the same as primary vaccine) SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
* Arm 2C: Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
* Arm 2D: Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
* Arm 2E: Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
Tissue biopsies are examined by reverse transcriptase-PCR, IHC, protein analysis, flow cytometry, and western blot. Blood samples are collected periodically and examined by ELIspot assay, tetramer staining, and proliferation assay.
After completion of study therapy, patients are followed annually.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1A
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
incomplete Freund's adjuvant
Given subcutaneously and intradermally
multi-epitope melanoma peptide vaccine
Given subcutaneously and intradermally
tetanus toxoid helper peptide
Given subcutaneously and intradermally
biopsy
Patients undergo surgical biopsy at replicate vaccine site
Arm 1B
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
incomplete Freund's adjuvant
Given subcutaneously and intradermally
multi-epitope melanoma peptide vaccine
Given subcutaneously and intradermally
tetanus toxoid helper peptide
Given subcutaneously and intradermally
biopsy
Patients undergo surgical biopsy at replicate vaccine site
Arm 1C
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
incomplete Freund's adjuvant
Given subcutaneously and intradermally
multi-epitope melanoma peptide vaccine
Given subcutaneously and intradermally
tetanus toxoid helper peptide
Given subcutaneously and intradermally
biopsy
Patients undergo surgical biopsy at replicate vaccine site
Arm 1D
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
incomplete Freund's adjuvant
Given subcutaneously and intradermally
multi-epitope melanoma peptide vaccine
Given subcutaneously and intradermally
tetanus toxoid helper peptide
Given subcutaneously and intradermally
biopsy
Patients undergo surgical biopsy at replicate vaccine site
Arm 1E
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (6 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
incomplete Freund's adjuvant
Given subcutaneously and intradermally
multi-epitope melanoma peptide vaccine
Given subcutaneously and intradermally
tetanus toxoid helper peptide
Given subcutaneously and intradermally
biopsy
Patients undergo surgical biopsy at replicate vaccine site
Arm 2A
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
incomplete Freund's adjuvant
Given subcutaneously and intradermally
multi-epitope melanoma peptide vaccine
Given subcutaneously and intradermally
tetanus toxoid helper peptide
Given subcutaneously and intradermally
biopsy
Patients undergo surgical biopsy at replicate vaccine site
Arm 2B
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
incomplete Freund's adjuvant
Given subcutaneously and intradermally
multi-epitope melanoma peptide vaccine
Given subcutaneously and intradermally
tetanus toxoid helper peptide
Given subcutaneously and intradermally
biopsy
Patients undergo surgical biopsy at replicate vaccine site
Arm 2C
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
incomplete Freund's adjuvant
Given subcutaneously and intradermally
multi-epitope melanoma peptide vaccine
Given subcutaneously and intradermally
tetanus toxoid helper peptide
Given subcutaneously and intradermally
biopsy
Patients undergo surgical biopsy at replicate vaccine site
Arm 2D
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
incomplete Freund's adjuvant
Given subcutaneously and intradermally
multi-epitope melanoma peptide vaccine
Given subcutaneously and intradermally
tetanus toxoid helper peptide
Given subcutaneously and intradermally
biopsy
Patients undergo surgical biopsy at replicate vaccine site
Arm 2E
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
incomplete Freund's adjuvant
Given subcutaneously and intradermally
multi-epitope melanoma peptide vaccine
Given subcutaneously and intradermally
tetanus toxoid helper peptide
Given subcutaneously and intradermally
biopsy
Patients undergo surgical biopsy at replicate vaccine site
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
incomplete Freund's adjuvant
Given subcutaneously and intradermally
multi-epitope melanoma peptide vaccine
Given subcutaneously and intradermally
tetanus toxoid helper peptide
Given subcutaneously and intradermally
biopsy
Patients undergo surgical biopsy at replicate vaccine site
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Either eligible for, but refused interferon therapy OR not a candidate for interferon therapy for the following reasons:
* Active ischemic heart disease or cerebrovascular disease
* Anginal syndrome requiring ongoing medications or history of myocardial infarction or arrhythmia disorder
* History of treatment for depression, active depression, or other psychiatric disorder
* Autoimmune disorders
* Hypersensitivity to interferon-alfa or any component associated with interferon therapy
* Debilitating medical conditions such as severe pulmonary disease or severe diabetes mellitus
* Thyroid abnormalities, where thyroid function cannot be maintained in the normal range without medication
* Resected stage IV melanoma
* Discontinued interferon therapy due to the occurrence of a major toxicity that has been documented by the treating physician
* Experienced tumor progression while on interferon or after completing interferon therapy
* Missed the standard-of-care enrollment window for interferon therapy initiation
PATIENT CHARACTERISTICS:
* ECOG performance status 0-1
* ANC \> 1,000/mm\^3
* Platelets \> 100,000/mm\^3
* Hemoglobin \> 9 g/dL
* AST and ALT ≤ 2.5 times upper limit of normal (ULN)
* Bilirubin ≤ 2.5 times ULN
* Alkaline phosphatase ≤ 2.5 times ULN
* Creatinine ≤ 1.5 times ULN
* Hepatitis C and HIV negative (antibody screening)
* Hemoglobin\_A1C level \< 7%
* Body weight ≥ 110 pounds
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during study treatment
* No New York Heart Association class III-IV heart disease
* No known or suspected allergies to any component of the vaccine
* No medical contraindication or potential problem in complying with the requirements of the protocol
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* Prior peptide vaccines (including MELITAC 12.1 and similar vaccines) or non-peptide vaccines allowed
* At least 1 week since prior stereotactic radiotherapy, such as gamma knife
* No influenza vaccine ≥ 2 weeks before, during, and ≥ 2 weeks after completion of study therapy
* More than 4 weeks since prior and no concurrent use of any of the following:
* Systemic cytotoxic chemotherapy (6 weeks for nitrosoureas)
* Radiotherapy
* Other experimental therapy
* Agents with putative immunomodulating activity (with the exception of non-steroidal anti-inflammatory agents and topical steroids)
* Allergy desensitization injections
* Systemic corticosteroids, administered parenterally or orally
* Inhaled steroids (e.g., fluticasone propionate \[Advair® or Flovent®\] or triamcinolone acetonide \[Azmacort®\])
* Topical corticosteroids and steroids with very low solubility administered nasally for local effects only allowed (e.g., mometasone furoate \[Nasonex®\])
* Growth factors (e.g., sargramostim \[GM-CSF\], filgrastim \[G-CSF\], or epoetin alfa)
* Interferon therapy
* Aldesleukin or other interleukins
* Street drugs
* At least 1 month since prior and no other concurrent investigational drugs or therapy
* At least 12 weeks since prior melanoma vaccine for patients who have recurred or progressed either after or during treatment with vaccine
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Craig L Slingluff, Jr
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Craig L Slingluff, Jr
Professor of Surgery; Director, Human Immune Therapy Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Craig L. Slingluff, MD
Role: PRINCIPAL_INVESTIGATOR
University of Virginia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Virginia Cancer Center
Charlottesville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pollack KE, Meneveau MO, Melssen MM, Lynch KT, Koeppel AF, Young SJ, Turner S, Kumar P, Sol-Church K, Mauldin IS, Slingluff CL Jr. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. J Immunother Cancer. 2020 Apr;8(1):e000544. doi: 10.1136/jitc-2020-000544.
Judge JM, Chianese-Bullock KA, Schroen AT, Slingluff CL Jr. Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial. Clin Trials. 2013 Feb;10(1):143-50. doi: 10.1177/1740774512464438. Epub 2012 Nov 29.
Schaefer JT, Patterson JW, Deacon DH, Smolkin ME, Petroni GR, Jackson EM, Slingluff CL Jr. Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J Transl Med. 2010 Aug 20;8:79. doi: 10.1186/1479-5876-8-79.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UVACC-MEL-48
Identifier Type: -
Identifier Source: secondary_id
UVACC-IRB-13498
Identifier Type: -
Identifier Source: secondary_id
UVACC-PRC-450-07
Identifier Type: -
Identifier Source: secondary_id
13498
Identifier Type: -
Identifier Source: org_study_id